{"nctId":"NCT00631319","briefTitle":"A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic Osteoarthritis (OA) Pain","startDateStruct":{"date":"2008-02"},"conditions":["Chronic Pain"],"count":343,"armGroups":[{"label":"OROS Hydromorphone","type":"EXPERIMENTAL","interventionNames":["Drug: OROS hydromorphone"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"OROS hydromorphone","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Primary clinic diagnosis of osteoarthritis pain of the hip or of the knee for at least 6 months\n* Patients required daily opioid medication to treat their chronic osteoarthritis pain\n\nExclusion Criteria\n\n* Joint replacement of the hip or of the knee that is the primary source of osteoarthritis Pain\n* History drug or alcohol abuse\n* Fibromyalgia\n* Patients who have major depression or anxiety\n* Women who are pregnant or breast feeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Patient Diary-derived Numeric Rating Scale (NRS) Pain Intensity Change From Baseline to Week 12 or Final Visit of the Double-blind Phase","description":"Participants rate their pain intensity on a numeric rating scale (NRS), where 0=no pain and 10=worst possible pain, in a daily diary. At Week 12 (or final visit), all measurements during the preceding week are averaged, and the mean change from the mean score at baseline is calculated.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"2.02"},{"groupId":"OG001","value":"0.6","spread":"1.87"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Patient Diary-derived Numeric Rating Scale (NRS) Pain Intensity and Change From Baseline by Visit in the Double-blind Phase","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score and Change From Baseline by Visit in the Double-blind Phase","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score and Change From Baseline by Visit in the Double-blind Phase","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score and Change From Baseline by Visit in the Double-blind Phase","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Patient Global Assessment and Change From Baseline by Visit in the Double-blind Phase","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Time to Treatment Failure From Baseline","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":338},"commonTop":["Constipation","Nausea","Headache","Vomiting","Somnolence"]}}}